Lawrence A Leiter
Leiter, Lawrence
VIAF ID: 85718386 (Personal)
Permalink: http://viaf.org/viaf/85718386
Preferred Forms
- 100 0 _ ‡a Lawrence A Leiter
- 100 1 _ ‡a Leiter, Lawrence
-
4xx's: Alternate Name Forms (5)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension | |
Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. | |
Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. | |
Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents -Post-hoc Analyses from DECLARE-TIMI 58 | |
Correctly understanding the diabetes data in FOURIER | |
The cost-effectiveness of dapagliflozin in treating high risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial | |
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease | |
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. | |
The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of LEADER and SUSTAIN 6 trials | |
The Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors in Overweight/Obese Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials | |
The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double-blind, randomized, controlled, acute feeding, equivalence trial | |
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study | |
Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin | |
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings | |
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide | |
Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial | |
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II | |
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study | |
Residual cardiovascular risk among people with diabetes | |
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials | |
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. | |
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure |